Curis (CRIS)
(Delayed Data from NSDQ)
$5.86 USD
-0.31 (-5.02%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $5.98 +0.12 (2.05%) 5:34 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Curis, Inc. [CRIS]
Reports for Purchase
Showing records 241 - 260 ( 305 total )
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
3Q11 UPDATE - VISMODEGIB MILESTONES TO DRIVE VALUE NEAR-TERM
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
VISMODEGIB NDA SUBMITTED - MULTIPLE MILESTONES IMMINENT
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
VISMODEGIB NDA SUBMITTED - MULTIPLE MILESTONES IMMINENT
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
2Q11 UPDATE - VISMODEGIB MOVES TOWARD APPROVAL IN US AND EU
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
2Q11 UPDATE - VISMODEGIB MOVES TOWARD APPROVAL IN US AND EU
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Home Run for BCC Patients - Pivotal Trial Results Are Unambiguous - Market Sizeable
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Home Run for BCC Patients - Pivotal Trial Results Are Unambiguous - Market Sizeable
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
SELL-OFF CREATES BUYING OPPORTUNITY - DATA, NDA, AND MILESTONES IMMINENT
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
SELL-OFF CREATES BUYING OPPORTUNITY - DATA, NDA, AND MILESTONES IMMINENT
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
1Q11 UPDATE - VISMODEGIB SUCCEEDS IN BCC - RAISING TARGET PRICE
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
1Q11 UPDATE - VISMODEGIB SUCCEEDS IN BCC - RAISING TARGET PRICE
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
GDC-0449 Meets Primary Endpoint in Advanced BCC Pivotal Trial - Potential Launch in 2012
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
GDC-0449 Meets Primary Endpoint in Advanced BCC Pivotal Trial - Potential Launch in 2012
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
A FOUR STAR A PATENTVEST IP GROWTH COMPANY - 2011 BEST AND BRIGHTEST PATENTVEST REPORTS
Provider: MDB CAPITAL GROUP LLC